Immunome's experimental drug meets main goal in late-stage study
Immunome's experimental drug achieved main goal in late-stage tumor study. Success indicates potential market approval for IMNM's innovative treatment.
View signal analysisCompany intelligence
IMNM
Immunome, Inc. · NASDAQ · Healthcare
Price$24.67-1.20% · −$0.30
Market cap2.36BEquity value
P / E-9.8Trailing ratio
Volume692.56KLatest session
Market data
TradingViewIMNM price chart
Related signals
1 min delayedLatest IMNM price-moving signals
Browse public IMNM signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
- Immunome, Inc. reported a quarterly loss of $0.34 per share, beating estimates by 57.50%. - The company posted revenues of $1.03 million, missing estimates by 74.28%. - Immunome shares have gained 45.9% YTD, outperforming the S&P 500. - Earnings outlook for Immunome is mixed, with a Zacks Rank #3 (Hold). - Industry outlook could impact stock performance, with Medical - Biomedical and Genetics ranking in the top 37%. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysisResearch